S. C. YAZGAN Et Al. , "Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis," Critical Reviews in Oncology/Hematology , vol.198, 2024
YAZGAN, S. C. Et Al. 2024. Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology , vol.198 .
YAZGAN, S. C., AKKUŞ, E., Yekeduz, E., & ÜRÜN, Y., (2024). Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology , vol.198.
YAZGAN, SATI Et Al. "Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis," Critical Reviews in Oncology/Hematology , vol.198, 2024
YAZGAN, SATI C. Et Al. "Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis." Critical Reviews in Oncology/Hematology , vol.198, 2024
YAZGAN, S. C. Et Al. (2024) . "Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis." Critical Reviews in Oncology/Hematology , vol.198.
@article{article, author={SATI COŞKUN YAZGAN Et Al. }, title={Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis}, journal={Critical Reviews in Oncology/Hematology}, year=2024}